Eli Lilly’s (LLY) Loxo and Foghorm (FHTX) Collaborate for Novel Oncology Targets using Foghorn’s Gene Traffic Control Platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
December 14, 2021 5:01 PM ESTEli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderately-to-severely... More
Foghorn’s (FHTX) Lilly/Loxo Deal is All-Around Positive, Validates Robust Drug Discovery Engine - Analyst
December 13, 2021 9:59 AM ESTEarlier today, Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development... More
Foghorn Therapeutics Inc. (FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (LLY)
December 13, 2021 6:15 AM ESTFoghorn Therapeutics Inc. (NASDAQ: FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (NYSE: LLY)
... More